European Companies Search Engine
EU funding (€8,784,039): Accelerating the lab to market transition of AI tools for cancer management Hor12 Jun 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Accelerating the lab to market transition of AI tools for cancer management
CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. An EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries. It will build on partner´s experience (e.g. PRIMAGE repository for paediatric cancer and the Euro-BioImaging node for Valencia population, by HULAFE; the Radiomics Imaging Archive by Maastricht University; the national repository DRIM AI France, the Oncology imaging biobank by Pisa University). Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed lung, prostate, colon and rectal cancer patients. A multimodal analytical data engine will facilitate to interpret, extract and exploit the right information stored at the Repository. An ambitious development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and images harmonisation, the latest being of the highest importance for enabling reproducibility of Radiomics when using large multiscanner/multicentre image datasets. The usability and performance of the Repository as a tool fostering AI experimentation will be validated, including a validation subphase by other world-class European AI developers, articulated via the organisation of Open Challenges to the AI Community. A set of selected AI tools will undergo early on-silico validation in observational (non-interventional) clinical studies coordinated by leading experts in Gustave Roussy (lung cancer), San Donato (breast), Sapienza (colon and rectal) and La Fe (prostate) hospitals. Their performance will be assessed, including external independent validation, on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer.
Funded Companies:
| Company name | Funding amount |
| Bahia Software SL | €512,188 |
| BC Platforms | €677,500 |
| BEN-Gurion University OF THE Negev | €466,250 |
| Charite - Universitaetsmedizin Berlin | €531,875 |
| College des Enseignants de Radiologie de France | €413,750 |
| Eibir Gemeinnutzige GmbH ZUR Forderung DER Erforschung DER Biomedizinischen Bildgebung | €263,750 |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | €1,113,125 |
| GE Healthcare GmbH | €567,685 |
| Imperial College of Science Technology and Medicine | €508,951 |
| Matical Innovation SL | €286,000 |
| Policlinico SAN Donato S.p.A. | €386,875 |
| Quibim SL | €458,750 |
| Unidade Local de Saude de Santo Antonio ΕΠΕ | €198,340 |
| Universita Degli Studi Di Roma LA Sapienza | €463,125 |
| Universita Di Pisa | €357,500 |
| Universitat de Valencia | €341,875 |
| Universitat Politecnica de Valencia | €658,188 |
| Universiteit Maastricht | €578,313 |
Source: https://cordis.europa.eu/project/id/952172
The filing refers to a past date, and does not necessarily reflect the current state.